Gallogly JA, et al. - Authors assessed the rates of tumor control, hearing preservation and cranial nerve toxicity with the use of CyberKnife stereotactic radiotherapy consisting of 2100 cGy to the 80% isodose line delivered in three weekly fractions to treat vestibular schwannomas. Tumor control consistent with current literature was provided by their fractionation regimen. Nonetheless, discussion of the hearing outcomes with patients prior to CyberKnife stereotactic radiotherapy was suggested. As per data, 45-months after SRT, one patient experienced trigeminal nerve toxicity. Among the patients who used CyberKnife stereotactic radiotherapy 95.5% were complication-free.